Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Baricitinib Promising for Juvenile Idiopathic Arthritis

Michele B. Kaufman, PharmD, BCGP  |  Issue: September 2022  |  July 19, 2022

EULAR 2022 (VIRTUAL)—A study found oral baricitinib (Olumiant) significantly reduced the time to and frequency of flares in patients aged 2–18 years with juvenile idiopathic arthritis (JIA).1 The findings of the study were presented by Athimalaipet Ramanan, MD, FRCPCH, FRCP, a consultant pediatric rheumatologist at Bristol Royal Hospital for Children and Royal National Hospital for Rheumatic Diseases, Bath, U.K., and Bristol Royal Hospital for Children, Bristol Medical School, Bristol, U.K.

Baricitinib is a Janus kinase (JAK) ½ selective inhibitor. In May 2018, the U.S. Food & Drug Administration (FDA) approved the agent to treat adults with moderate to severe active RA for whom one or more tumor necrosis factor (TNF) antagonist therapies had proved inadequate.2 In a phase 3 study, Ramanan et al. investigated baricitinib’s safety and efficacy in pediatric patients with JIA for whom conventional or biologic disease-modifying anti-rheumatic drugs (DMARDs) had proved inadequate.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Participants in this double-blind, withdrawal study included patients with extended oligoarticular or polyarticular JIA, enthesitis-related arthritis (ERA) or juvenile psoriatic arthritis (jPsA) according to the International League of Associations for Rheumatology (ILAR) criteria.

Study Design

The study was divided into three periods: a two-week pharmacokinetic and safety assessment; a 12-week, open-label, lead-in period; and a 32-week, double-blind withdrawal period. Safety and dosing were confirmed during the pharmacokinetic and safety assessment period. Patients enrolled in the open-label, lead-in period then received age-based, once-daily doses of baricitinib. Patients who achieved a JIA ACR30 response at week 12 entered the study’s double-blind withdrawal phase. In the double-blind withdrawal period, patients were randomized in a 1:1 ratio to continue baricitinib treatment or begin baricitinib withdrawal, receiving placebo until disease flare or week 32.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The primary study end point was the time to flare during the double-blind withdrawal period. Secondary end points included the proportion of patients experiencing a flare during the double-blind withdrawal period and the JIA ACR30/50/70/90 response rates at week 12. Survival curves were estimated using the Kaplan-Meier method.

The Results

In total, 219 patients entered the study’s second phase—the 12-week, open-label, lead-in period—and 163 patients entered the 32-week, double-blind withdrawal period.

At week 12, 76.3% of patients achieved a JIA ACR30 response, 63.5% of patients achieved a JIA ACR50 response, 46.1% of patients achieved a JIA ACR70 response and 20.1% of patients achieved a JIA ACR90 response. During the double-blind withdrawal period, the proportion of patients who experienced a disease flare was significantly lower in the baricitinib treatment group (17.1%) than the placebo group (50.6%; P<0.001).

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsDrug UpdatesEULAR/OtherMeeting ReportsPediatric Conditions Tagged with:baricitinibEULARflareJIAjuvenile idiopathic arthritis (JIA)PediatricPediatric Rheumatology

Related Articles

    What Adult Rheumatologists Need to Know about Juvenile Arthritis

    May 1, 2013

    How to recognize distinctions between pediatric and adult arthritis

    Oksana Kuzmina/shutterstock.comx

    Environmental Factors in Pediatric Systemic Autoimmune Diseases

    March 20, 2017

    Systemic autoimmune diseases are thought to result from immune dysregulation in genetically susceptible individuals who were exposed to environmental risk factors. Many studies have identified genetic risk factors for these diseases, but concordance rates among monozygotic twins are 25–40%, suggesting that nonheritable environmental factors play a more prominent role.1,2 Through carefully conducted epidemiologic and other…

    Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA

    April 20, 2017

    Brodalumab Approved for Plaque Psoriasis The U.S. Food and Drug Administration has approved brodalumab, a monoclonal antibody that targets interleukin 17 (IL‑17).1,2 Brodalumab (Siliq) was approved for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and have failed to respond to, or have lost response to, other…

    Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA

    March 7, 2017

    In a recent study, baricitinib proved more effective than adalimumab in treating adults with RA through 52 weeks…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences